ECT, or electroconvulsive therapy, is a medical procedure in which a controlled electrical current is delivered through the skull to trigger a brief, generalized seizure in the brain. It is performed under general anesthesia and is primarily used to treat severe depression that hasn’t responded to medication. Despite decades of stigma, modern ECT has a response rate of about 73% and a remission rate of 51% for moderate to severe depression, making it one of the most effective treatments in psychiatry.
How the Electrical Transmission Works
During ECT, electrodes placed on the scalp deliver a train of short, rectangular electrical pulses that alternate in polarity. These pulses are defined by a few key characteristics: how strong the current is, how long each pulse lasts, how frequently the pulses repeat, and how long the entire burst of pulses continues. The electrical field generated is significantly stronger than what’s needed to activate neurons, ensuring that a full seizure is reliably produced.
Modern devices use constant-current pulses rather than the older constant-voltage approach. Each individual pulse lasts only a fraction of a millisecond. Standard “brief pulse” settings use pulse widths between 0.5 and 2.0 milliseconds, but the field has shifted toward “ultrabrief” pulses of around 0.2 to 0.3 milliseconds. Ultrabrief pulses appear to work just as well while causing fewer cognitive side effects. In terms of voltage, seizure thresholds typically fall in the range of 110 to 250 volts, though clinicians adjust the dose for each patient.
The strong electrical stimulation produces synchronized, rhythmic firing across large populations of neurons. This coordinated activity is what constitutes the therapeutic seizure, which typically lasts 20 to 60 seconds. The seizure itself, not simply the electrical stimulus, is believed to drive the treatment’s benefits.
Where the Electrodes Go
The path the electrical current travels through the brain depends on electrode placement, and clinicians choose from three main configurations. Bilateral placement (with electrodes on both temples or both sides of the forehead) is preferred when rapid symptom improvement is the priority. Right unilateral placement, where one electrode sits on the right temple and the other on the top of the head, is chosen when minimizing cognitive side effects matters most. The seizure threshold is lower with unilateral placement, meaning less electrical energy is needed to produce a seizure.
In practice, the choice often comes down to balancing speed of recovery against memory side effects. Bilateral ECT tends to work faster and may be more effective in the most severe cases, while right unilateral ECT at higher doses can achieve comparable results with less impact on memory.
What Happens During the Procedure
You’re put under general anesthesia before any electrical current is delivered. The anesthesia serves three purposes: keeping you unconscious, preventing pain, and maintaining stable heart rate and blood pressure. After you’re sedated, a muscle relaxant is administered to prevent your body from physically convulsing during the seizure. Without it, the involuntary muscle contractions could cause injuries. The seizure still occurs in the brain, but its visible physical effects are reduced to minor twitching, usually monitored through a blood pressure cuff inflated on one foot or hand.
The entire electrical stimulus lasts only a few seconds. Including preparation, anesthesia, the treatment itself, and a short recovery period, each session takes roughly 30 to 45 minutes. A typical course involves two to three sessions per week over three to six weeks.
What ECT Does to the Brain
The therapeutic effects of ECT appear to work through several biological pathways simultaneously, which is part of why it’s so effective and also why researchers have spent decades trying to pin down a single explanation.
One well-documented effect involves dopamine signaling. Research in primates undergoing a clinical ECT protocol showed increases in dopamine-related activity in the brain’s reward and movement centers within 24 to 48 hours of treatment. These changes were transient, returning to baseline by six weeks, but the temporary boost in dopamine transmission may help explain ECT’s rapid antidepressant effects and its occasional use in Parkinson’s disease. ECT also appears to alter other chemical messenger systems differently than antidepressant medications do, suggesting it works through a distinct mechanism.
Perhaps the most compelling finding is that ECT promotes structural changes in the brain. Neuroimaging studies have shown that both the hippocampus (critical for memory and emotional regulation) and the amygdala (involved in processing emotions) increase in volume during a course of ECT. These volume increases are not just a byproduct of repeated seizures. They correlate directly with symptom improvement: patients whose hippocampal volume grew more tended to experience greater reductions in depression scores. The growth appears driven by neuroplasticity processes including the formation of new neurons, new synaptic connections, and new blood vessels. Volume deficits linked to depression actually normalize toward healthy levels.
Conditions ECT Treats
The FDA has cleared ECT devices for six indications: unipolar depression, bipolar depression, bipolar mania and mixed states, schizophrenia, schizoaffective disorder, schizophreniform disorder, and catatonia. In the United States, the vast majority of ECT is used for unipolar depression, typically after one or more medications have failed.
ECT is considered a primary (first-line) treatment when the clinical situation is urgent. Active suicidal behavior, severe weight loss or malnutrition from depressive loss of appetite, and psychosis with dangerous agitation are all scenarios where the speed of ECT’s response makes it the best option. For mania, its use is uncommon and reserved for cases that have resisted other treatments.
Memory and Cognitive Side Effects
Memory disruption is the side effect that concerns most people considering ECT, and it’s a legitimate concern worth understanding in detail. There are two distinct types of memory impact.
The first is difficulty forming new memories during and shortly after the treatment course. This impairment begins early in treatment and can persist for a few days after the final session. By two weeks after the last treatment, the ability to learn and retain new information typically returns to baseline. Objective testing beyond 14 days shows no measurable impairment in new learning.
The second type is loss of existing memories, particularly from the months leading up to treatment. Memory loss is usually most pronounced for the three months immediately before ECT but can sometimes reach back a year or more. Most of this retrograde memory loss improves significantly within six months. However, some memories from that period, especially personal autobiographical memories of specific events, may not return. Objective studies tracking patients for at least a year have found that some degree of memory loss persists, and it seems unlikely that memories still absent after a year would spontaneously come back.
Ultrabrief pulse ECT and right unilateral electrode placement both reduce the severity of these cognitive effects compared to older techniques, which is a major reason the field has moved in that direction.
Safety Profile
A systematic review pooling data from 32 countries and over 766,000 ECT treatments found a mortality rate of 2.1 deaths per 100,000 treatments. For context, general anesthesia for surgical procedures carries a mortality rate of 3.4 per 100,000. Among studies published after 2001, covering more than 414,000 treatments, only a single ECT-related death was reported. Death from ECT is an extremely rare event by any medical standard.